StockNews.com initiated coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT – Free Report) in a research report sent to investors on Friday. The firm issued a hold rating on the stock.
Separately, HC Wainwright reiterated a buy rating and issued a $19.00 target price on shares of Oncternal Therapeutics in a research note on Friday, May 31st.
Get Our Latest Stock Analysis on Oncternal Therapeutics
Oncternal Therapeutics Stock Performance
Oncternal Therapeutics (NASDAQ:ONCT – Get Free Report) last released its earnings results on Thursday, May 9th. The company reported ($2.83) earnings per share for the quarter, beating the consensus estimate of ($2.88) by $0.05. Oncternal Therapeutics had a negative net margin of 3,160.73% and a negative return on equity of 107.67%. The business had revenue of $0.57 million during the quarter, compared to analysts’ expectations of $0.18 million. During the same quarter last year, the company earned ($4.00) earnings per share. Research analysts forecast that Oncternal Therapeutics will post -11.63 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Oncternal Therapeutics news, Director Robert James Wills purchased 3,086 shares of the company’s stock in a transaction that occurred on Monday, April 8th. The stock was purchased at an average price of $8.96 per share, with a total value of $27,650.56. Following the completion of the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $89,600. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Company insiders own 11.20% of the company’s stock.
Institutional Trading of Oncternal Therapeutics
A hedge fund recently bought a new stake in Oncternal Therapeutics stock. Quantum Private Wealth LLC acquired a new position in shares of Oncternal Therapeutics, Inc. (NASDAQ:ONCT – Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 27,806 shares of the company’s stock, valued at approximately $250,000. Quantum Private Wealth LLC owned approximately 0.94% of Oncternal Therapeutics at the end of the most recent quarter. Institutional investors and hedge funds own 16.05% of the company’s stock.
About Oncternal Therapeutics
Oncternal Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of oncology therapies for cancers with critical unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like Orphan Receptor 1 (ROR1); and ONCT-216, a small molecule inhibiting the biological activity of ETS-family transcription factor oncoproteins, which is in Phase 1/2 clinical trial.
Recommended Stories
- Five stocks we like better than Oncternal Therapeutics
- The Significance of Brokerage Rankings in Stock Selection
- These Top 3 Banks Raise Dividends After Passing Fed Stress Test
- Should You Add These Warren Buffett Stocks to Your Portfolio?
- Hitch a Ride with Lyft Stock for Double-Digit Gains in 2nd Half
- How to Calculate Retirement Income: MarketBeat’s Calculator
- Eli Lilly Stock Up: GLP-1 Zepbound Targets Sleep Apnea Market
Receive News & Ratings for Oncternal Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncternal Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.